mike_nyc said:One third of STEP 4 participants held most of their loss without the drug, and nobody has convincingly characterised who they are.
The regain framing needs pushing back on. Two thirds regained means one third did not, and the trial provided no ongoing support to either group. Treating regain as pharmacologically inevitable is as unsupported as treating maintenance as automatic.
One concrete data point for the thread. Post reference ranges alongside numbers when you share them. Units differ by country — glucose and lipids especially — and half the confusion in these threads is unit mismatch rather than disagreement.
SarahChen_PharmD said:The regain framing needs pushing back on.
Adding the part of the answer the thread has not reached. The single most useful discipline is bringing the whole panel to a clinician rather than one flagged value. One out-of-range result in isolation generates anxiety and unnecessary tests; the same result next to the trend and the rest of the panel usually generates a shrug.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsOne thing that is still open after pete_nash’s answer:
Whether extending the interval works as well as reducing the dose, since they are not the same intervention pharmacologically?
Closing the loop on my own question.
I went to a lower dose rather than a longer interval on the strength of the trough argument in this thread, and the difference in how even it feels is obvious.